Patient groups
Articles focused on children and teens with Crohn's disease or IBD, including pediatric research, care, and family context.
Page 3 of 6 · 253 articles
Both EEN and the Crohn’s disease exclusion diet are used to induce remission in children with Crohn’s disease. Evidence that they perform similarly through 52 weeks may help families and clinicians choose the approach...
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
If you or a child had Kawasaki disease, this study suggests there may be a higher long-term chance of certain skin autoimmune conditions (psoriasis, vitiligo) but no clear increase in IBD or several other autoimmune...
Physical activity may be a modifiable factor that could improve fitness, inflammation, symptoms like fatigue, and quality of life in children with IBD. This trial will provide objective, randomized data relevant to...
Researchers used machine learning and molecular docking plus small animal tests to link a common plasticizer (DEP) with molecular changes seen in pediatric Crohn’s disease. This could point to environmental exposures...
Clear, reproducible ultrasound definitions for transmural healing and response could help clinicians track deeper intestinal healing beyond mucosal assessment and allow trials to use consistent imaging endpoints.
This study reports that combining an anti-TNF-α drug with vedolizumab helped many children with IBD who failed single-biologic therapy achieve clinical, endoscopic, and histologic improvement. It also notes serious...
Label changes for RENFLEXIS affect people with Crohn's disease or ulcerative colitis who take (or may be prescribed) infliximab biosimilars — the label includes dosing, age indications, and important safety warnings that...
A cellular atlas that links diagnostic biopsy cell states to treatment outcomes could help predict which children are likely to have severe or anti‑TNF‑resistant Crohn's disease, informing future research on personalized...
The FDA approval expands an approved biologic option (ustekinumab/Stelara) to children aged two and older with moderately to severely active ulcerative colitis, giving families and clinicians another treatment choice. It...
Growth impairment is a key concern in pediatric Crohn's disease; knowing which children are more likely to regain weight or height and how treatments like infliximab relate to growth can affect monitoring and treatment...
Patient-derived intestinal organoids offer a human-relevant platform that could improve understanding of pediatric IBD biology and help predict individual treatment responses — potentially reducing trial-and-error...
Anaemia is a common and impactful complication in children diagnosed with IBD; knowing how often it occurs, which subtypes are most frequent, and its link with disease activity can guide monitoring and management...
Thiopurines are commonly used in IBD (azathioprine, 6-mercaptopurine). This review links these drugs — especially 6-thioguanine — to liver microvascular injury that can lead to portal hypertension, which may present...
The study suggests that modifiable early-life factors (breastfeeding, diet, antibiotic exposure, etc.) may be linked to later IBD risk, especially Crohn's disease. That could inform future prevention research and...
Clinical trials shape available treatments and evidence; if groups of children (by race, ethnicity, or sex) are underrepresented, study results may not reflect how treatments work for them. This paper identifies...
Cure8 could only read part of this source from The American Journal of Gastroenterology, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and...
This registry will track long-term safety and clinical outcomes in children with IBD, with a focus on infliximab (an anti‑TNF biologic) versus non‑biologic therapies. Long follow-up could help identify uncommon or late...
A strategic, pediatric-focused research agenda helps target studies where children with IBD and related conditions most need better diagnostics, biomarkers, and treatments. Prioritizing multi-center registries and...
Pediatric IBD affects growth, nutrition, puberty, and long-term quality of life, so families and clinicians need to recognize its broader impacts and the importance of coordinated multidisciplinary care.
The study suggests that modifiable early-life factors (feeding, antibiotic exposure, activity, BMI, smoke exposure, delivery mode, diet) may influence the later risk of IBD, especially Crohn's disease, which could be...
A pediatric Phase 2 trial testing etrasimod could expand treatment options for children with moderately to severely active ulcerative colitis if later shown safe and effective. Families of affected children and their...
Growth and nutrition are common concerns in children with IBD because poor weight gain and short stature can affect long‑term health and development.
Cure8 found this source from Journal of paediatrics and child health, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Upadacitinib. Open the original...
IBD-U means no clear Crohn’s or ulcerative colitis diagnosis yet — that uncertainty can affect treatment decisions and follow-up. The review highlights tests that may help clarify diagnosis and stresses that many...
People with pediatric IBD-like intestinal inflammation, or caregivers, may encounter overlapping autoimmune conditions such as large-vessel vasculitis; recognizing that intestinal biopsy can be nondiagnostic is...
Capsule endoscopy can safely help diagnose small-bowel disease in very young children, including cases of suspected IBD, and may be particularly helpful when blood tests or imaging suggest inflammation or low albumin....
Early-onset IBD affects children worldwide and the commentary highlights that although deaths are declining, more children are living with IBD and social inequalities are widening — issues that can affect access to care,...
This study suggests that using 5‑ASA drugs early in children with Crohn’s disease was common but linked to more steroid use, delayed biologic treatment, and lower biologic durability — outcomes that matter for long‑term...
The study links changes in gut microbes and microbial functions with disease activity in children with IBD, suggesting the microbiome may play a role in recovery and could be a target to help sustain remission.
Perianal fistulas are a common and morbid complication of Crohn's disease in children; a reliable, less burdensome imaging tool could help assess severity and monitor response to therapy more often than MRI.
People with CGD commonly have liver involvement and some develop IBD-like intestinal disease; recognizing and monitoring these complications may affect care and outcomes.
Parents and clinicians may wonder whether stressful events in early life increase a child’s long-term IBD risk. This large prospective study found no evidence that the measured early maternal or family adverse events...
Children with IBD can develop idiopathic acute pancreatitis that is often mild but may recur; knowing this helps families and clinicians monitor and manage pancreatic symptoms during active disease and after surgery.
In young children, enteric infections can mimic or coexist with VEO‑IBD and change imaging and clinical findings; recognizing both can affect diagnosis and treatment choices.
Recognizing eye inflammation as a possible early sign of IBD could shorten diagnostic delays and lead to earlier gastroenterology evaluation and treatment, which is especially important for children who often wait years...
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
A local Pediatric IBD Day helps children, families and care teams connect, learn practical skills for daily life with IBD, and reduces the burden of travelling for specialized pediatric care. For families in...
Drug levels and how patients reach remission can differ depending on prior biologic use. For families and clinicians managing pediatric Crohn's, this can affect how infliximab dosing and monitoring are interpreted after...
Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.
VTE is a serious, potentially preventable complication in children with newly diagnosed IBD. Identifying risk factors could help clinicians consider which pediatric patients might need closer monitoring or future...
A new pediatric Phase 3 trial of filgotinib could broaden approved treatment choices for children and teens with moderate-to-severe ulcerative colitis, especially for those who have not responded to or cannot tolerate...
Finding neutralising anti-IL-10 antibodies in a subset of children with IBD may help explain why some patients have more severe, treatment‑resistant disease and points to a potential biomarker for risk stratification.
Back-to-school planning can reduce emergencies and missed care for students with chronic conditions, including Crohn’s disease. Preparing plans, communicating with school or campus staff, and knowing where to get care...
This study aims to identify which clinical or biological factors predict treatment response and serious complications in children with newly diagnosed IBD — information that could help tailor care for pediatric patients...
Intestinal ultrasound is a noninvasive imaging option that can help detect and monitor bowel inflammation without radiation. A new local program could improve access to this tool for people with IBD, including children.
Predicting who will respond to anti-TNF drugs could help avoid ineffective treatments, reduce delays to effective therapy, and personalize care for children with Crohn's disease.
This pooled analysis focuses on children with IBD and reports that ustekinumab was associated with substantial clinical and steroid-free remission rates and a low incidence of serious adverse events—information that may...
